Client was a small pre-IPO biopharma start up with a <$100 million valuation
Client had recently completed a small but interesting phase 2 clinical trial demonstrating expected results
Challenge
Client organization and investigational candidate were unknown to the investment as well as scientific/medical community, making financing to fund further development a challenge
Investigators in the client’s clinical trials were not well known in the scientific and medical community
Client had a competitor that was significantly further along in development with their entire clinical development program completed, had well known physicians investigators and supporters, and was already well funded
The Xelay Approach
In less than a year, Xelay Acumen created and implemented an innovative best-in-class strategic approach to market communications, preparation, and shaping which directly led to 2 rounds of financing ($75M) and a $600M IPO
Two years later, client organization was acquired for $2.7 billion
